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1 Introduction 
1.1 The need for guidance 
In Scotland, alcohol consumption in women of childbearing age is common and is recognised as 
a significant public health issue. While surveys show a pattern of decline in self-reported alcohol 
consumption in Scotland, the majority of women still drink some alcohol. This proportion has decreased 
from 87% in 2003 to 82% in 2017 with the abstinence rate among women aged 16–34 years being 
18%, falling to 13% in 35–44 year olds. Women in the least deprived areas are most likely to drink 
and those in most deprived areas are least likely to drink at all, but those living in deprivation 
who do drink are more likely to drink heavily.1 Alcohol consumption in women of childbearing age 
reflects the consumption across the population and the whole population approach adopted by the 
Scottish Government, informed by World Health Organization guidance, is designed to reduce general 
consumption.2
Alcohol consumption in pregnancy has the potential to cause significant fetal damage.3-5 While no 
woman wishes to intentionally harm her unborn child, this preventable cause of damage to the fetus 
continues to occur for a variety of reasons. In 1973, a cluster of birth defects resulting from prenatal 
alcohol exposure was first described as a clinical entity called fetal alcohol syndrome (FAS).6 The 
syndrome has been characterised with specific diagnostic criteria which include evidence of prenatal 
alcohol exposure, evidence of structural or functional central nervous system (CNS) abnormalities, a 
specific pattern of three facial abnormalities and growth impairment (either prenatally, after birth 
or both). 
As experience with children prenatally exposed to alcohol grew, other definitions were introduced in 
an attempt to provide better descriptions of a range of clinically diverse presentations. Such terms 
have included ‘fetal alcohol effects’ (FAE) which was used to describe children whose behaviour 
and cognitive function were assumed to have been affected by prenatal alcohol exposure (PAE) but 
whose growth and facial features, as well as global cognitive function, were normal or did not meet 
specific deficits. Further terms used in this situation include ‘alcohol-related birth defects (ARBD), 
alcohol-related neurodevelopment disorder (ARND), partial fetal alcohol syndrome (pFAS)’ and 
‘neurodevelopmental disorder – prenatal alcohol exposure (ND-PAE)’ (see section 1.3). 
These wider patterns of effects, along with FAS, constitute the continuum of structural anomalies and 
neurocognitive and behavioural disabilities associated with prenatal exposure to alcohol which has 
been labelled fetal alcohol spectrum disorder (FASD).
It is estimated that PAE detrimentally affects 7.7 per 1,000 population worldwide (95% confidence 
interval (CI) 4.9 to 11.7) with prevalence of FASD in the UK rising to 32.4 per 1,000 (95% CI 20.0 
to 49.0) making neurodevelopmental disorder related to PAE one of the commonest preventable 
causes of impairment.7-9 In Scotland, many fewer children than predicted by international studies 
in similar populations are identified as having been affected by PAE, suggesting that we are failing 
to identify, and therefore adequately support, these children. Between 2010 and 2015 a passive 
surveillance study funded by the Chief Scientist’s Office and Child and Maternal Health Division of 
Scottish Government, identified only 41 reported cases of FAS.10 The study recorded diagnoses in 
children below the age of six years.
Based on clinical experience and published evidence, the reasons for this low incidence reporting 
include:
 y  failure to consider PAE as a possible cause of neurodevelopmental delay and/or behavioural 
difficulties11 
 y a lack of standardised diagnostic approach and training in its use12
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 y a lack of expertise and/or confidence in making the diagnosis13 
 y non-referral for appropriate assessment of children suspected of having significant PAE11
 y  reluctance to make the diagnosis, as this is perceived as unhelpful or more damaging than not 
making the diagnosis11,14
 y additional substance abuse in mothers which overshadows the features of FASD.15 
Currently, for many children PAE is not considered and/or acknowledged as a possible cause of their 
neurodevelopmental disorder, particularly those children with attention deficit and hyperkinetic 
disorders (ADHD) and autism spectrum disorder (ASD). This may contribute to an adverse outcome 
for the child, and, just as importantly, misses the opportunity to protect subsequent pregnancies. 
Information from New Zealand and Canada suggests that identification of FASD can be a potent 
motivator for mothers to abstain from alcohol in subsequent pregnancies.16
Although birth mothers are generally reticent in identifying themselves because of the stigma attached 
to the diagnosis, those who present their views publicly confirm that they would have been better 
able to manage their child’s difficulties if they had understood the underlying brain damage that the 
child had sustained. Staff in the education sector may also be more supportive if they are aware of 
alcohol-related prenatal brain damage in a child.
With the development of better, more targeted, educational and social support programmes for these 
children and their families there is an urgent need to make the appropriate diagnosis at the earliest 
opportunity. Early diagnosis and intervention from birth and in the first years of life can make 
significant differences to the developmental progress of the affected child, and better understanding of 
the condition can help parents and professionals cope more appropriately with the child’s difficulties.17
Poor awareness and lack of training in available standardised diagnostic and screening tools for 
healthcare staff may result in the failure to recognise these children. Additionally, alcohol use may 
be overshadowed by other substance use in mothers,15 which may result in poor recording of alcohol 
use in the context of illicit substance use. 
FASD is a lifelong condition. If difficulties are not anticipated and understood, educational opportunities 
will not be optimised and some affected children and young people will have poor educational 
attainment, develop mental health problems, have a higher risk of becoming addicted to alcohol 
and other drugs thus continuing the cycle.18 These children and young people are also more likely 
to become involved in criminal activity,18,19 and die prematurely from violence, accident or suicide.20 
Evidence suggests that receiving an accurate and early diagnosis allows parents and carers to best 
accommodate the child’s environment to meet their needs and allows access to early interventions 
that may help to prevent secondary disabilities.21,22 
1.1.1 Patient perspective
Patients may have different perspectives on healthcare processes and outcomes from those of 
healthcare professionals. The involvement of patients in developing guidance is therefore important 
to ensure that guidance reflect their needs and concerns and address issues that matter to them.
Common concerns raised by patient and carer groups and through research include:
 y late diagnosis and difficulties in accessing services 
 y poor communication between different agencies involved in assessment and management
 y accuracy of diagnosis
 y the perceived lack of confidence among healthcare professionals in making a diagnosis of FASD
 y coping with challenging behaviour or symptoms before a diagnosis is made
 y  lack of follow up of ‘at risk’ individuals exposed prenatally to alcohol but who have not yet 
displayed signs or symptoms of FASD.
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1.2 Remit of the document
1.2.1 Overall objectives
This document provides recommendations based on best available evidence and consensus for the 
assessment and diagnosis of children and young people affected by PAE. It includes evidence-based 
recommendations on measurement of alcohol consumption in pregnancy and consensus-based 
recommendations on:
 y identification of children at risk of FASD
 y criteria for diagnosis and use of FASD as a descriptor
 y medical assessment
 y physical examination
 y sentinel features
 y neurodevelopmental assessment
 y the multidisciplinary assessment team
 y special considerations in the neurodevelopmental assessment 
 y management and follow up of children and young people affected by PAE. 
Detailed treatment options for individuals affected by PAE are not included.
1.2.2 Comorbidities to consider when managing patients at risk of FASD
Common comorbidities and coexisting health issues which have been considered when reviewing the 
evidence for this guidance are:
 y ADHD
 y ASD
 y mood disorders.
1.2.3 Target users
These recommendations will be of interest to individuals involved in the assessment and diagnosis of 
people at risk of FASD, including child development specialists, clinical and educational psychologists, 
clinical geneticists, general practitioners (GPs) and members of the primary care team, health visitors, 
members of the judicial system, midwives, neonatologists, nurses (eg school, learning disability 
and others), obstetricians, occupational therapists, paediatricians, physicians, physiotherapists, 
psychiatrists, social workers and speech and language therapists. It will also be of interest to people 
at risk of FASD, their parents and carers, adoptive and fostering services, supportive organisations 
in the voluntary sector and policy makers.
1.2.4 Patient version
A patient version is available from the Scottish Intercollegiate Guidelines Network (SIGN) website, 
www.sign.ac.uk
1.3 Definitions and terminology
Diagnosis is based on a thorough history and examination, however, because alcohol has broad and 
varied effects on brain development, there is no unique clinical pattern of impairment that is sensitive 
or specific enough to confirm the diagnosis of FASD. A number of diagnostic criteria exist (see Table 
1). Although these criteria share some common features, differences exist in terminology which may 
be confusing and be associated with lower confidence in reaching a valid diagnosis.
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1.3.1 Existing diagnostic criteria
The Institute of Medicine (IOM) criteria for fetal alcohol syndrome were published in 1996 and provided 
the first systematic approach to delineating diagnostic categories for children adversely affected by 
prenatal alcohol exposure.23 They were developed by a panel of experts, based on review of a large 
number of children with clinical abnormalities who were born in the USA following confirmed prenatal 
alcohol exposure. An update was published in 2005 which revised the diagnostic criteria for FAS and 
pFAS and defined alcohol-related birth defects (ARBD) and alcohol-related neurodevelopmental disorder 
(ARND).24 A second update was published in 2016 which included cut-off points for measurements of 
growth and palpebral fissure length and stricter criteria for ARBD.25
The IOM diagnostic categories are: 
 y FAS, 
 y partial FAS, 
 y ARND, and 
 y ARBD.
The Fetal Alcohol Spectrum Disorders 4-digit diagnostic code was developed in 2000 to ensure 
objectivity and reproducibility in the diagnosis of FAS through specifying cut-off points (for example, 
for growth parameters and palpebral fissure length).26 The concept of the 4-digit diagnostic code was 
introduced to give greater diagnostic scope for describing children adversely affected by alcohol but 
who did not fulfil the diagnostic criteria for FAS. This system introduces the use of a number of other 
terms to describe clinical patterns, including the terms ‘static encephalopathy – alcohol exposed’, and 
‘neurobehavioural disorder - alcohol exposed’.
There are a total of 256 diagnostic codes arranged into 22 diagnostic categories in the 4-digit 
diagnostic code system:
 y FAS (alcohol exposed)
 y FAS (alcohol exposure unknown)
 y partial FAS (alcohol exposed)
 y FAS phenocopy (no alcohol exposure)
 y sentinel physical finding(s) / static encephalopathy (alcohol exposed)
 y static encephalopathy (alcohol exposed)
 y sentinel physical finding(s) / neurobehavioural disorder (alcohol exposed)
 y neurobehavioral disorder (alcohol exposed)
 y sentinel physical finding(s) (alcohol exposed)
 y no sentinel physical findings or CNS abnormalities detected (alcohol exposed)
 y sentinel physical finding(s) / static encephalopathy (alcohol exposure unknown)
 y static encephalopathy (alcohol exposure unknown)
 y sentinel physical finding(s) / neurobehavioural disorder (alcohol exposure unknown)
 y neurobehavioural disorder (alcohol exposure unknown)
 y sentinel physical finding(s) (alcohol exposure unknown)
 y no sentinel physical findings or CNS abnormalities detected (alcohol exposure unknown)
 y sentinel physical finding(s) / static encephalopathy (no alcohol exposure)
 y static encephalopathy (no alcohol exposure)
 y sentinel physical finding(s) / neurobehavioural disorder (no alcohol exposure)
 y neurobehavioural disorder (no alcohol exposure)
 y sentinel physical finding(s) (no alcohol exposure)
 y no sentinel physical findings or CNS abnormalities detected (no alcohol exposure).
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A committee of experts, mandated by US federal law, was convened by the Centers for Disease Control 
and Prevention (CDC) to update and refine the diagnostic criteria for FAS in 2004.27 Only criteria for 
FAS were developed because there was deemed to be lack of evidence to support the development 
of reliable diagnostic criteria for the rest of the spectrum. The committee then introduced the term 
FASD as an umbrella term to encompass the full range of individuals along a broad continuum of 
clinical deficits related to PAE.
The first Canadian guideline for diagnosis of FASD, published in 2005, included elements of both the IOM 
criteria and the 4-digit diagnostic code and provided specific cut-off values for growth parameters.28 
The criteria for CNS involvement were more stringent than other classifications, requiring evidence 
of deficits in three or more CNS domains. An updated version of the guideline, published in 2016, 
was the first system to recommend the use of the term FASD as a diagnostic classification rather 
than a collective category.29 It removed growth impairment as a diagnostic criterion and modified 
the domains of neurodevelopmental deficit required for diagnosis. 
The Canadian diagnostic categories are:
 y FASD with sentinel facial features
 y FASD without sentinel facial features.
A further designation of ‘at risk for neurodevelopmental disorder and FASD, associated with prenatal 
alcohol exposure’ was introduced to describe individuals with confirmed PAE and some indication of 
neurodevelopmental concerns, who do not meet the criteria for either of the FASD diagnostic categories.
While FAS is a clinical diagnosis, reached through any of the systems noted above, ND-PAE is a new 
psychiatric diagnosis introduced in the Diagnostic and Statistical Manual of Mental Disorders fifth 
edition (DSM-5) classification in 2014.30 It is included as an appendix representing a condition requiring 
further study, however, is also used as an example of ‘other specified neurodevelopmental disorder’, 
(code 315.8). The current International Classification of Diseases 10th revision (ICD-10) includes a 
diagnostic description for fetal alcohol syndrome. A further diagnosis of ‘neurodevelopmental syndrome 
due to prenatal alcohol exposure’, reserved for patients in whom no other neurodevelopmental disorder 
can be diagnosed, is anticipated with the implementation of the 11th revision in 2022. 
A study assessed the consistency and differences between five diagnostic systems for FASD in 
1,581 consecutively registered patients, ages 0 to 21, who applied for a multidisciplinary diagnostic 
evaluation at a university-based clinic specialising in the care of children with prenatal alcohol and 
drug exposure.31 Despite overlapping diagnostic criteria, there was only fair to moderate agreement 
between diagnostic outcomes across the five systems, with different systems resulting in the proportion 
of participants who received any FASD-related diagnosis ranging from 4.74% to 59.58%. The authors 
noted that rather than representing a matter of degree, for example an individual receiving a 
diagnosis of pFAS in one system, and a diagnosis of FAS in another (based on the number of criteria 
required in each system) there were cases where an individual might be diagnosed with FAS in one 
system and receive no diagnosis in another. This lack of convergent validity was ascribed to a range 
of factors, including the fact that there is no gold standard for diagnosis against which to measure 
competing systems. In addition, there is a wide variety of measures and thresholds in meeting the 
neurodevelopmental diagnostic criteria and there is inconsistency among them. The choice of facial 
features across different diagnostic approaches have not, in general, been made using empirical 
evidence but rather rely on clinical judgement. The authors note that the concordance between 
systems is improved when diagnostic categories are collapsed into FASD versus no diagnosis. Such 
an approach is designed into the 2016 Canadian system. 
A comparison of diagnostic criteria for FAS across different systems is contained in Table 1.
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Table 1: Comparison of five international systems for diagnosis of FAS(D)
At least 1 of the following:
• Structural/ neurological:
 -  Decreased cranial size  
at birth
 -  Abnormal structure  
(eg microcephaly, 
partial/complete 
agenesis of the corpus 
callosum, cerebellar 
hypoplasia)
 -  Neurological hard/ 
soft signs
At least 1 of the following:
• Low birth weight
• Low weight for height
• Decelerating weight
At least 1 of the following:
• Structural
 - OFC <10th percentile
 - Abnormal structure
Prenatal and/or postnatal 
height or weight
• <10th percentile
At least 1 of the  
following:
•  Structural/ neurological: 
(eg OFC <3rd percentile, 
abnormal structure, 
seizure disorder, hard 
signs)
•  Severe dysfunction: 
(3 or more domains 
of function with 
impairment 2 or more 
SDs below the mean)
Prenatal and/or postnatal 
height or weight
• <10th percentile
Diagnostic term FAS
Confirmed-excessive  
or unknown
Characteristic pattern that 
includes features such  
as short PFL, flat upper lip, 
flattened philtrum,  
and flat midface. 
FAS
Confirmed-excessive  
or unknown
2 or more of the following:
• PFL <10th percentile
•  Smooth philtrum  
Rank 4 or 5
•  Thin upper lip 
Rank 4 or 5 
All 3 of the following at 
any age:
• PFL < 3rd percentile
•  Smooth philtrum  
Rank 4 or 5
•  Thin upper lip 
Rank 4 or 5 
22 terms 
Confirmed or unknown
IOM (1996) Revised IOM (2005) 4-digit (2000)
Prenatal alcohol  
exposure 
Neuro developmental 
impairment
Facial features
Growth 
impairment
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At least 3 of the following 
domains with impairment:
•  Hard/soft signs, 
structure, cognition, 
communication 
academic achievement, 
memory, executive 
functioning, abstract 
reasoning, ADD, 
adaptive behaviour, 
social skills, or 
communication
At least 1 of the following:
•  Prenatal and/or 
postnatal height or 
weight <10th percentile
•  Weight-to-height ratio 
(<10th percentile)
At least 3 of the following 
domains with impairment:
• motor skills
•  neuroanatomy/ 
neurophysiology
• cognition
• language
• academic achievement
• memory
• attention
•  executive function, 
including impulse 
control and 
hyperactivity
• affect regulation, and 
•  adaptive behaviour, 
social skills or social 
communication
N/A
At least 3 of the following 
domains with impairment:
• motor skills
•  neuroanatomy/ 
neurophysiology
• cognition
• language
• academic achievement
• memory
• attention
•  executive function, 
including impulse 
control and 
hyperactivity
• affect regulation, and 
•  adaptive behaviour, 
social skills or social 
communication
N/A
At least 1 of the following:
•  Structural/neurological: 
(eg OFC <10th percentile, 
abnormal structure, 
seizure disorder, hard/
soft signs)
• Dysfunction:
 -  3 or more domains 
of function with 
impairment 1 or more 
SDs below the mean
 -  Global deficit (2 or 
more SDs below the 
mean)
Prenatal and/or postnatal 
height or weight
• <10th percentile
All 3 of the following at 
any age:
• PFL <3rd percentile
•  Smooth philtrum  
Rank 4 or 5
•  Thin upper lip  
Rank 4 or 5 
All 3 of the following at 
any age:
• PFL <3rd percentile
•  Smooth philtrum  
Rank 4 or 5
•  Thin upper lip  
Rank 4 or 5 
All 3 of the following at 
any age:
• PFL <3rd percentile
•  Smooth philtrum 
Rank 4 or 5
•  Thin upper lip  
Rank 4 or 5 
<3 of the following:
• PFL <3rd percentile
•  Smooth philtrum 
Rank 4 or 5
•  Thin upper lip 
Rank 4 or 5 
FAS
Confirmed or unknown
FAS
Confirmed or unknown
FASD with sentinel facial 
features
Confirmed or unknown
FASD without sentinel 
facial features 
Confirmed
CDC (2004) Canadian (2005) Canadian (2015)
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1.3.2 Terminology
In addition to differences between the diagnostic criteria included in existing published systems (see 
section 1.3.1) there are also differences in terminology used to describe symptoms and impairments. 
In order to facilitate recognition of the adverse effects of PAE in Scotland and contribute to ongoing 
international research, the working group felt that using contemporary worldwide terminology would 
be beneficial. In adopting the most recent Canadian Guidelines, which recognise FASD with or without 
sentinel features as diagnostic categories, we believe that it is clinically and practically useful to define 
and identify these two groups of affected individuals. 
We acknowledge that this terminology does not match the ICD-10 and DSM-5 classifications, in which 
only FAS (presence of sentinel facial features alongside developmental delay and typical behavioural 
characteristics – similar to the Canadian FASD with sentinel facial features diagnosis) and ND-PAE, 
respectively, are recognised as diagnostic categories. We intend to use the Canadian terminology 
‘FASD without sentinel features’ (which describes cases with confirmed prenatal alcohol exposure 
and severe pervasive neurodevelopmental impairment in the context of fewer than three sentinel 
facial features) as a descriptor rather than a diagnostic term. 
We also acknowledge that the way in which the Canadian guideline uses the term ‘domain’ to identify 
both anatomical structure, and individual areas of assessment of brain function is conceptually 
problematic. The term does, however, allow for easier identification of at least three differing areas of 
brain impairment; this is critical in attributing dysfunction to PAE, and is an internationally accepted 
term.
In this document we will denote ‘domain’ as an area of assessment. 
1.4 Origin of this guidance
The topic of diagnosis of FAS and FASD was accepted by SIGN for development as an evidence-based 
clinical guideline. However, the systematic literature review conducted to inform this guideline 
identified insufficient relevant evidence of adequate quality to support the development of evidence-
based recommendations (with the exception of the issue of screening for alcohol consumption during 
pregnancy). The literature review also identified the existence of a number of published consensus 
guidelines on the topic, and the guidance development group explored these in further detail to 
determine whether these could be used in Scotland. The group agreed that development of a new 
consensus guideline for Scotland without reference to existing guidance would not be practical or 
efficient and may increase the inconsistencies between different diagnostic systems used across the 
world (see section 1.3.1). After assessment, the group concluded that adaptation of the revised Canadian 
guideline on diagnosis of FASD29 offered the best balance of methodological quality and clinical topic 
coverage. Elements of the Australian guide to the diagnosis of FASD have also been incorporated.32
The multidisciplinary development group has derived this guidance, with permission, from the 
Canadian guideline developers by considering each recommendation from the source in detail and 
making minor revisions to align the guidance with practice in Scotland. This includes differences in 
the use of diagnostic criteria for behavioural conditions in the two countries. In Scotland, diagnoses 
are generally made on the basis of the classification developed by the World Health Organization 
(ICD-10), whereas DSM-5 is used in Canada. The rationale for these revisions is explained in the 
body of this guidance. Where the group felt specific advice was not required, recommendations have 
been excluded. The supporting text which underpins each recommendation is drawn mostly from the 
Canadian guideline with additional material and references added from the SIGN systematic review. 
The only new recommendations added are drawn from the evidence-based review of the literature 
on screening for alcohol use during pregnancy (see section 2.1.3). Further details on the methods used 
to develop this guidance are contained in section 6.2.
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1.4.1 Layout of the guidance
In order to maintain the integrity of the consensus process used by the Canadian guideline developers 
in the formulation of their recommendations, this guidance has preserved as much of the original 
recommendations as possible, and made only minor revisions to the wording to align these with 
the Scottish context. These revisions are fully described in the guidance and the original Canadian 
recommendations are listed in Annex 3. To allow the reader to understand the source of the information 
in this document, text which is taken from the Canadian guideline is reproduced within green boxes. 
Text generated by the Scottish development group does not appear in boxes (unless replacing or 
adding to Canadian text in which case it appears in a grey font). In section 2.1 a recommendation has 
been reproduced from the UK Chief Medical Officers’ Low Risk Drinking Guidelines and is reproduced 
within a dark blue box for clarity.
1.5 Statement of intent
This guidance is based on the consensus developed by a clinical expert group and is not intended to 
be construed or to serve as a standard of care. Standards of care are determined on the basis of all 
clinical data available for an individual case and are subject to change as scientific knowledge and 
technology advance and patterns of care evolve. Adherence to recommendations will not ensure a 
successful outcome in every case, nor should they be construed as including all proper methods of 
care or excluding other acceptable methods of care aimed at the same results. 
The ultimate judgement must be made by the appropriate healthcare professional(s) responsible 
for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement 
should only be arrived at through a process of shared decision making with the patient, covering the 
diagnostic and treatment choices available. It is advised, however, that significant departures from 
the national guidance or any local guidelines derived from it should be documented in the patient’s 
medical records at the time the relevant decision is taken.
1.5.1 Influence of financial and other interests
It has been recognised that financial interests in, or close working relationships with, pharmaceutical 
companies may have an influence on the interpretation of evidence from clinical studies.
It is not possible to completely eliminate any possible bias from this source, nor even to quantify 
the degree of bias with any certainty. SIGN requires that all those involved in the work of guideline 
development should declare all financial interests, whether direct or indirect, annually for as long 
as they are actively working with the organisation. By being explicit about the influences to which 
contributors are subjected, SIGN acknowledges the risk of bias and makes it possible for guideline 
users or reviewers to assess for themselves how likely it is that the conclusions and guideline 
recommendations are based on a biased interpretation of the evidence.
Signed copies of declaration of interests forms are retained by the SIGN Executive and a register of 
interests is available in the supporting material section for this guidance at www.sign.ac.uk
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2 Identification of children at risk of FASD
The current consideration of FASD as a cause of neurodevelopmental dysfunction is very poor in 
Scotland. Identification of potentially-affected children depends on the clear recording of alcohol 
consumption in women of childbearing age, particularly those planning to become pregnant, or 
presenting in the antenatal period. Proactive routine recording of alcohol consumption during pregnancy 
and access to this information across key clinical and social stakeholders is important. This section 
looks at methods of recording alcohol intake and initiating referral for comprehensive assessment 
of effects caused by PAE.
2.1 Maternal alcohol history
A reliable and accurate maternal alcohol history is the best screening tool for identifying risk of 
FASD. It is therefore critical for service providers to effectively and appropriately determine alcohol 
use among all women of childbearing age. A variety of factors can impact a woman’s consumption of 
alcohol during pregnancy,33 including a prior history of alcohol consumption,34,35 a family background 
of alcohol use,23,36 a history of inpatient treatment for problematic alcohol and/or substance use 
and/or a history of mental health problems,37,38 the previous birth of a child with FASD,36,39 lack of 
contraception/unplanned pregnancy,37 a history of physical/emotional/sexual abuse,37 low income 
and/or limited access to health care.34,37,38 
At the request of the UK Chief Medical Officers (CMOs), three groups of independent experts reviewed 
evidence from over 40 systematic reviews and meta-analyses; consulted with international experts and 
the Committee on Carcinogenicity on the effects of alcohol on a range of cancers and commissioned new 
modelling of the impact of alcohol consumption on morbidity and mortality, based on UK population 
data. In making their recommendations to the UK CMOs, the expert group took account of evidence 
of risks and benefits, but noted that studying the effects of low levels of alcohol on the fetus was 
difficult, not least because women will not know they are pregnant at the earliest stages. They noted 
that relevant good-quality studies were few, meaning that, despite little evidence of harm from low 
levels of drinking, it was not possible to say that such drinking carries no risks of harm to the fetus 
at all. It is plausible scientifically that alcohol, even at such low levels, could cause some harm. Based 
on evidence that risks of low birth weight, preterm birth, and being small for gestational age may 
all be increased in mothers drinking above 1–2 units/day during pregnancy and the need for clarity 
and simplicity in providing helpful advice for women and the uncertainties that exist about any 
completely safe level, the CMO guideline recommended a ‘precautionary’ approach that it is safest to 
avoid drinking any alcohol in pregnancy.40 
The Chief Medical Officers’ guideline is that:
 y  if you are pregnant or think you could become pregnant, the safest approach is not to drink 
alcohol at all, to keep risks to your baby to a minimum
 y  drinking in pregnancy can lead to long-term harm to the baby, with the more you drink the 
greater the risk.
The risk of harm to the baby is likely to be low if you have drunk only small amounts of alcohol 
before you knew you were pregnant or during pregnancy.
If you find out you are pregnant after you have drunk alcohol during early pregnancy, you should 
avoid further drinking. You should be aware that it is unlikely in most cases that your baby has been 
affected. If you are worried about alcohol use during pregnancy do talk to your doctor or midwife.
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There is no known safe level of alcohol consumption during pregnancy. Even low to moderate levels 
of PAE can negatively impact a fetus and these adverse consequences can persist into adulthood.41-44 
A lack of access to accurate antenatal health records can be a significant barrier to diagnosis. It is 
critical for healthcare providers to discuss alcohol use during pregnancy, to document concerns 
and to ensure that appropriate supportive follow-up care is provided. Although information about 
quantity, frequency and pattern of alcohol consumption during pregnancy is important, it is difficult 
to determine for a number of reasons, including under-reporting.45,46
R  All pregnant and postpartum women should be screened for alcohol use with validated 
measurement tools by service providers who have received appropriate training in their 
use. All women should be advised not to consume alcohol in pregnancy; additionally those 
women drinking above the low-risk guideline for the general population should be offered 
early, brief interventions (ie counselling and/or other services).
    Women identified as having a pattern of risky or harmful alcohol use should be offered an 
intervention appropriate to their needs. This could range from a single structured conversation 
about alcohol risk (a brief intervention) to intensive treatment including detoxification and 
relapse prevention work.
Rationale for revision
Canadian recommendations 1.1 and 1.3 have been amalgamated for impact and clarity. The revision 
brings the recommendation in line with Scottish Government drinking limits rather than the more 
vague “risk of heavy alcohol use”. 
2.1.1 Assessing likely prenatal alcohol exposure
As most of the published data relating to drinking alcohol during pregnancy are collected from 
mothers either prospectively or retrospectively, they may be inherently flawed. Studies have shown 
that women tend to under-report (or not report) their alcohol consumption during pregnancy.47-49
The presence of all three facial features has such high specificity to prenatal alcohol exposure and 
FASD that confirmation of alcohol exposure is not required when they are present. The presence 
of fewer than three facial features does not have the same degree of specificity and therefore 
requires other confirmation.
R  Confirmation of PAE requires documentation that the biological mother consumed alcohol 
during the index pregnancy based on:
 y reliable clinical observation 
 y self report or reports by a reliable source 
 y medical records documenting positive blood alcohol concentrations, or 
 y  alcohol treatment or other social, legal or medical problems related to drinking during 
the pregnancy.
Rationale for revision
Canadian recommendation 2.2 noted that in the presence of all three facial sentinel features, 
confirmation of prenatal alcohol exposure was not required to make an FASD diagnosis. However, the 
development group felt that introduction of the sentinel facial features within the recommendation was 
not directly relevant to screening for alcohol use. Furthermore, in the absence of confirmed alcohol 
exposure, there are a number of possible genetic causes which may account for facial dysmorphology. 
We have therefore moved the reference to facial features to the supporting text and added a statement 
to the recommendation in section 3.1.1 that genetic causes should be considered (and excluded, where 
possible) before arriving at a diagnosis/descriptor of FASD. 
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2.1.2 Recording the pattern of alcohol consumption
Differences in gender, ethnicity, history and genetics50-52 are some of the factors influencing or 
contributing to alcohol’s effects, as is the timing, frequency and quantity of alcohol consumed. 
Although dose per occasion is likely more important than drinking frequency,53 binge drinking does 
occur in all types of prenatal alcohol consuming women – low/light, moderate and heavy.
R  The number of type(s) of alcoholic beverages consumed (dose), the pattern of drinking and 
the frequency of drinking in pregnancy should all be documented.
    This information should be routinely recorded by the midwife in antenatal notes and 
communicated to the GP and Health Visitor in Transfer of Care documentation. This will ensure 
that PAE information (confirmed/confirmed absent/unknown) will be more easily accessed 
and remain within the child’s health records.
R  Sources for confirmed prenatal alcohol history must be reliable and devoid of any conflict 
of interest. Unsubstantiated information, lifestyle alone, other drug use or history of alcohol 
exposure in previous pregnancies cannot, in isolation, confirm alcohol consumption in the index 
pregnancy. However, co-occurring disorders, significant psychosocial stressors and prenatal 
exposure to other substances (eg smoking, licit or illicit drugs) in the index and previous 
pregnancies should still be recorded, based on the known interactions of these substances 
and their effects on pregnancy outcomes for both the mother and her offspring.
Rationale for revision
Canadian recommendation 2.3 has been retained in full and clarified that the documentation should 
refer to alcohol consumption during pregnancy. Canadian recommendation 2.4 has been retained in full.
2.1.3 Screening for prenatal alcohol exposure
While a number of systematic reviews and primary and pilot studies were identified by literature 
searching, following appraisal, only a few studies were considered by the group to answer this key 
question (see Annex 1) and be of adequate methodological quality. Three systematic reviews were 
identified that included evidence which addressed parts of the key question. The reviews were 
heterogeneous and addressed different research questions.
The first systematic review included studies involving brief screening questionnaires to identify 
drinking of alcohol in pregnancy.54 All major screening tests were included. The findings showed 
that T-ACE, TWEAK and AUDIT-C could be helpful in screening for risky drinking, however, the 
authors recommended caution noting that further evaluations of questionnaires for prenatal alcohol 
consumption should be undertaken. (Evidence level 2++)
A further systematic review investigated the effectiveness of blood biomarkers.55 Eight studies met 
the inclusion criteria and included a variety of blood biomarkers. Despite the included studies being 
rated as good methodological quality, none of the biomarkers had both high sensitivity and specificity 
compared with self report. There was some evidence that a combination of biomarkers, or combining 
biomarkers with self report, may increase accuracy. However, the blood biomarkers examined were of 
limited use in screening for low and moderate alcohol consumption in pregnancy compared with self 
report, although the authors stated that certain biomarkers such as carbohydrate deficient transferrin 
(CDT) and phosphatidylethanol (PEth) may complement self report and help improve the accuracy of 
diagnosis. (Evidence level 2++)
The third systematic review also explored the objective measures of biomarkers of prenatal alcohol 
exposure.56 Eight biomarkers were assessed across 12 studies of heterogeneous populations, including 
women from particular high-risk groups. The authors concluded that the evidence reviewed was 
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insufficient to support the use of objective measures of prenatal alcohol exposure in practice. (Evidence 
level 2++)
There was some inconsistency between the two systematic reviews which assessed biomarkers in that 
one review cautiously suggested the use of certain measures such as CDT and PEth during pregnancy 
in complementary use, alongside women’s self report,55 while the other did not view biomarkers to 
have clear value in practice.56 The latter review highlighted meconium and placental tissue as the 
objective measures with most promise, but this is only relevant to retrospective examination of levels 
of alcohol use once the pregnancy is over and therefore provides little opportunity to intervene when 
prevention of harm is still possible.
The development group also considered the relevance of this evidence to the Scottish population and 
the balance of benefits and harms of the proposed intervention. The group concluded that there are 
risks associated with not asking pregnant women about their alcohol use as there is then a missed 
opportunity to provide information about what is known about the risks of alcohol consumption 
in pregnancy and to support women with health behaviour change in this area. No evidence was 
identified to suggest that asking about alcohol history had a detrimental effect on attendance for care. 
There has been a national standard (formerly a Health Improvement, Efficiency, Access and Treatment 
(HEAT) target) on the delivery of alcohol brief interventions (ABIs) in antenatal settings since 200857 
and therefore questions about alcohol have been routinely asked of pregnant women in Scotland by 
antenatal providers. Some group members did caution, however, that in their experience, adopting 
screening tools in isolation does not necessarily ensure that alcohol consumption in pregnancy is 
discussed effectively. The ‘booking in’ visit is one opportunity to ask questions sensitively about alcohol, 
as well as discussing other issues in the woman’s life of relevance to her pregnancy,58 such as paying 
due attention to potential risk factors such as high social class and experiences of violence and abuse. 
To enable health behaviour change, including reduction in alcohol consumption during pregnancy, 
supportive relationships between patients and caregivers are key.59 (Evidence levels 2++, 2+ and 3)
The evidence highlights important additional issues for healthcare professionals and others concerned 
with the health and well-being of women of childbearing age and their children. For example, the 
likelihood that women drinking at higher and more problematic levels are least likely to accurately 
describe their alcohol use when asked has been reported.60 Group members also expressed concern, 
based on their experience of implementing alcohol screening and ABIs in response to Scottish 
Government targets, that the validated screening tools did not contain language that was easily 
articulated in Scotland. At least one Scottish health board includes broad alcohol screening questions 
in the electronic maternity record rather than using a validated screening tool. Early identification and 
prompt intervention, based on the use of screening tools to support self-reported alcohol use during 
pregnancy, may benefit women and their families, including those affected by FASD. Recording an 
accurate alcohol history might, in turn, support a more thorough signposting process for additional 
support to obtain a diagnosis of FASD, which is a key issue for families. Nevertheless, group members 
were concerned that no evidence was identified which directly links a maternal history that has 
involved alcohol use to improved rates of diagnosis and better outcomes for a woman or her children. 
(Evidence level 2+)
R  Use of the T-ACE, TWEAK or AUDIT-C tools in screening women in the antenatal period for 
alcohol consumption should be considered.
R  Associated use of particular biomarkers, such as CDT and Peth, alongside brief screening 
questionnaires, should be considered.
A sample FASD assessment form, which includes sections for collection of maternal alcohol consumption 
in early pregnancy and standardised screening tools for alcohol exposure in pregnancy is available 
for download from the SIGN website.
2  |  Identification of children at risk of FASD
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2.1.4 Referral
A lack of knowledge and understanding of FASD among healthcare professionals means they often 
may not feel competent to carry out an assessment and make an appropriate diagnosis. Variation in 
knowledge and awareness poses a significant challenge to the implementation of a comprehensive 
and consistent approach to the management of FASD.61
Practitioners require to have a sound knowledge and understanding of the key principles of Scottish 
Government’s practice models Getting It Right for Every Child (GIRFEC)62 and Getting Our Priorities 
Right (GOPR)63 when undertaking any assessment of need in relation to a child considered likely to 
be affected by maternal alcohol consumption.
R  Referral of individuals for consideration of PAE as a cause of possible neurodevelopmental 
disorder should be made sensitively and only when there is evidence of significant physical, 
developmental or behavioural concerns and probable PAE.
Rationale for revision
In Canadian recommendation 1.2, referral was phrased to confirm a diagnosis of FASD only. In Scotland, 
the development group felt that referral should be for an assessment which may lead to a range 
of outcomes, which include the diagnosis of a neurodevelopmental disorder, diagnosis of FASD 
with sentinel facial features, descriptor of FASD without sentinel facial features or identification 
of other impairment not associated with any specific diagnosis. To avoid unmanageable increases 
in inappropriate referrals for any woman who has consumed significant amounts of alcohol during 
pregnancy, a referral should not be made in the absence of accompanying physical or developmental 
concerns in the child or young person. The development group also noted the potential for assessment 
or diagnosis to cause anxiety and stigma and emphasised that the process should be undertaken with 
sensitivity.
15
3  |  Identification and assessment of children and young people affected by prenatal alcohol exposure
3 Identification and assessment of children and young 
people affected by prenatal alcohol exposure
Prenatal alcohol exposure should be actively considered as a possible underlying cause for 
neurodevelopmental delay, or an unexplained departure from a typical developmental profile. This 
section considers the process for assessment of those at risk of having been adversely affected by PAE 
and the criteria for application of the diagnosis/descriptor of FASD with or without sentinel features.
3.1 Diagnostic criteria
3.1.1 FASD
The term FASD was originally coined as an umbrella term to encompass a range of diagnoses (FAS, 
pFAS, FAE, ARND, ARBD) and the breadth of disabilities associated with PAE.28 With the evolution of 
FASD-related language within different professions, it is critical to adopt standardised terminology 
wherever possible. Standard terminology and definitions are important for comparing data across 
different geographical settings.
R  A diagnosis of FASD with sentinel facial features* may be made if an individual meets the 
following criteria:
 y  simultaneous presentation of the three sentinel facial features (short palpebral fissures, 
smooth philtrum and thin upper lip); AND
 y  prenatal alcohol exposure confirmed or unknown; AND
 y  evidence of severe impairment in three or more of the identified neurodevelopmental 
areas of assessment or, in infants and young children, presence of microcephaly.
R  A descriptor of FASD without sentinel facial features† may be used if an individual meets the 
following criteria:
 y confirmation of prenatal alcohol exposure; AND
 y  evidence of severe impairment in three or more of the identified neurodevelopmental 
areas of assessment.
R
 For both diagnoses:
 y  Contribution of genetic factors should be considered in all cases and referral may be 
indicated in atypical cases or where PAE is uncertain.
 y  Growth impairment and other birth defects and/or health issues should be documented 
if present.
 y  Hereditary, prenatal and postnatal factors that may influence developmental outcome 
should be recorded.
*  This has similarities to the diagnostic category FAS in ICD-10 and the diagnostic category ND-PAE 
in DSM-5
† There is no equivalent diagnostic category in ICD-10 or DSM-5
Rationale for revision
This recommendation is consistent with Canadian recommendation 5.1. “Severe” impairment has been 
added into this recommendation to make consistent with Canadian recommendations 4.1 and 4.2. 
Microcephaly (head circumference <2nd percentile for age) is either present or absent, so this is a simple 
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language clarification. Alcohol exposure is made consistent with Scottish Government recommendations 
on limits. Given the possible aetiological link between certain physical and neurodevelopmental 
impairments and genetic causes, the group felt it important that these are excluded before a diagnosis 
or descriptor of FASD is reached and have added a bullet point for consideration. The definition and 
use of the term ‘neurodevelopmental domain’ is now referred to as an area of assessment (see section 
1.3.2).
Standardised growth charts for UK boys and girls aged 0–4 years (©Department of Health 2009), 
and UK boys and girls aged 2–18 years (© Royal College of Paediatrics and Child Health 2012/13) 
which include WHO standards and UK birth and preterm data are available for download from the 
SIGN website.
R The diagnostic/descriptive criteria for FASD are the same for adults as for younger individuals.
Rationale for revision
Canadian recommendation 8.1 has been retained in full. 
3.1.2 At risk for neurodevelopmental disorder and FASD
The designation ‘at risk for neurodevelopmental disorder and FASD, associated with prenatal alcohol 
exposure’ was created to describe individuals who have confirmed prenatal alcohol exposure and 
some indication of neurodevelopmental concerns, but who do not meet the criteria for either of the 
FASD categories. It is especially germane for young children. Research64 and clinical observation 
suggest that some individuals who have been prenatally exposed to alcohol may develop normally 
at younger ages or show only mild deficits. Later, when reassessed, significant impairments become 
evident as they fail to develop the higher-level thinking skills that are the norm for their age. At 
the older ages a more comprehensive assessment can be conducted. The designation of ‘at risk’ 
when they are younger is important and may enable them to access services and supports, with 
the recommendation that a follow-up assessment in the future be done to confirm FASD or not. 
Postnatal factors that may influence developmental outcome (for example nutrition, stress or 
trauma) must always be considered and recorded.
R  The designation ‘at risk for neurodevelopmental disorder and FASD, associated with prenatal 
alcohol exposure’ should be given to individuals when:
 y there is confirmation of prenatal alcohol exposure
 y the CNS diagnostic/descriptive criteria for FASD are not met (see above) 
 y  there is some indication of neurodevelopmental disorder in combination with a plausible 
explanation as to why the neurodevelopmental assessment results failed to meet the 
criteria for significant impairment (for example patient was too young; assessment was 
incomplete etc).
In addition:
 y Growth impairment and other congenital anomalies should be documented if present.
 y  Hereditary, prenatal and postnatal factors that may influence developmental outcome 
should be recorded.
Rationale for revision
The phrase from Canadian recommendation 5.2.1 “the estimated dose at a level known to be associated 
with neurodevelopmental effects” which was used to describe a threshold for PAE has been removed 
to make consistent with the UK CMO advice for no safe level of alcohol consumption during pregnancy. 
A note has been added to reflect the possible outcome of assessment being a descriptor of FASD 
without sentinel facial features. The term ‘birth defects’ has been replaced with congenital anomalies. 
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R  The designation ‘at risk for neurodevelopmental disorder and FASD, associated with prenatal 
alcohol exposure’ may also be considered for individuals with all three sentinel facial features 
as described above who do not yet have documentation or evidence of abnormality in the 
requisite three or more neurodevelopmental area of assessment criteria or microcephaly. This 
designation should never be considered when prenatal alcohol exposure is confirmed absent.
Rationale for revision
This recommendation is consistent with Canadian recommendation 5.2.2. The term ‘domain’ has been 
replaced with area of assessment (see section 1.3.2).
3.1.3 The use of FASD as a diagnostic term
In some other diagnostic systems, the term FASD is not used as a diagnostic category (see Table 1).23,25-28 
Based on recommendations in the Canadian guideline, we are recommending the adoption of FASD 
with sentinel facial features as a diagnostic term.29 While the features associated with FASD represent 
a spectrum of effects, the severity of neurodevelopmental effects in all areas of assessment is not 
dependent upon whether facial features are present or absent.
R  FASD should now be used as a diagnostic/descriptor term when prenatal alcohol exposure is 
considered to be a significant contributor to observed deficits that cannot be fully explained 
by other aetiologies. Because the observed deficits are recognised as being multifactorial in 
origin, all other known relevant contributors (for example trauma or known genetic anomalies) 
should be documented with the FASD diagnosis/descriptor  as they have significant impact 
on the functional and neurological challenges of the affected individuals.
See Annex 2 for a diagnostic algorithm for FASD.
Rationale for revision
This recommendation is consistent with Canadian recommendation 5.3. In the Scottish context, we 
intend to use the Canadian terminology FASD without sentinel features as a descriptor rather than a 
diagnostic term (see section 1.3.2).
A sample FASD assessment summary, which includes sections for recording alcohol exposure in 
pregnancy, sentinel facial features and neurodevelopmental areas of assessment is available for 
download from the SIGN website.
3.2 Medical assessment
It is critical that FASD is recognised as a physical, behavioural and neurodevelopmental health 
condition. Family history must be reviewed and, if possible, a three-generation family tree obtained. 
This allows the team to identify existing developmental disorders in the family and identify the 
potential for inheritable disorders, based on an occurrence in the parents, siblings or second- or third-
generation relatives. Consanguinity in the parents may indicate a risk of certain inherited disorders. 
The presence of FASD in other siblings is a risk factor for having another affected child.39,65-68
Several structural deficits and/or birth defects involving the ears, eyes, palmar creases, digits, elbow, 
joints and heart have been associated with FASD. Children with FASD are also at increased risk of 
additional structural defects including congenital heart defects and orofacial clefts.69-71
R  The diagnostic process should include a family, social and medical history as well as complete 
physical examination.
Rationale for revision
A minor revision from Canadian recommendation 2.1 ensures that family history is gathered.
3  |  Identification and assessment of children and young people affected by prenatal alcohol exposure
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A sample FASD assessment form, which includes sections for collection of obstetric, developmental, 
medical and social history; other medical conditions and genetic and other investigations is available 
for download from the SIGN website.
3.3 Sentinel facial features
3.3.1 Overview
There is evidence to support the recommendation that the simultaneous presentation of the three 
characteristic facial features that discriminate individuals with PAE include:
 y short palpebral fissures, 
 y indistinct philtrum and 
 y thin upper lip.64,72 
In a longitudinal analysis that explored which facial measures were most predictive of prenatal 
alcohol exposure and whether the measurements changed with age, a set of 16 facial measurements 
were selected. The data revealed that measures of craniofacial width (minimal frontal), orbital 
width (palpebral fissure width) and ear and mandibular measures (ear length and lower facial 
depth) were consistently predictive of group membership across age groups (5 and 9 years old).73 
After evaluating a computational model that could be used to accurately identify children with 
FAS automatically using facial features from 3D scans, researchers found that prenatal alcohol 
exposure not only produced the specific dysmorphic features – short palpebral fissures, thin upper 
lip and flat philtrum – but also other more subtle features that made the overall gestalt of an 
FASD face.74 Although variations in the facial features associated with prenatal alcohol exposure 
were found across different sample populations using computerised anthropometry, at least one 
measure involving the eye (for example shortened palpebral fissures, reduced outer canthal width, 
or reduced inner canthal width) was apparent in all of them,75 suggesting that the palpebral fissure 
length measurement is particularly sensitive to PAE. Overall, the findings were consistent with the 
clinical description of facial features involving the orbital region (palpebral fissure size) and mid 
face (mid-facial hypoplasia and thin upper lip with flat philtrum) as discriminating features of PAE. 
Using data from active case ascertainment studies of three distinct populations of children with 
PAE, similarities and differences in dysmorphology, growth, and unique physical features were 
explored.76 After combining the populations, their model revealed that the following variables predict 
dysmorphology unambiguously: small palpebral fissures, narrow vermillion, smooth philtrum, flat 
nasal bridge, and fifth finger clinodactyly. 
FASD diagnostic data64 revealed that the presence of all three sentinel facial features and 
microcephaly (head circumference ≥2 standard deviations (SD) below the mean) in children, who 
were old enough to undergo a complete neurodevelopmental assessment (>8 years), was always 
associated with significant neurodevelopmental impairment. Therefore, infants and young children 
presenting with all three sentinel facial features and microcephaly may receive a formal diagnosis 
of FASD with sentinel facial features, even if they have yet to meet the criteria for significant 
neurodevelopmental impairment.
3.3.2 Assessing the face
The University of Washington Lip-Philtrum Guides continue to be the standard for an objective 
evaluation of lip and philtrum development. As described by the FAS Diagnostic and Prevention 
Network (depts.washington.edu/fasdpn/htmls/lipphiltrum-guides.htm), the Lip-Philtrum Guides 
reflect the full range (or normal distribution) of lip thickness and philtrum depth one would see in 
a general population. The Rank 3 picture reflects the population mean (or 50th percentile). Ranks 
1 and 5 reflect the extreme ends of the normal curve (<2.5th percentile and >97.5th percentile). 
In practice, the Lip-Philtrum Guides have been described as a Likert scale (which has often been 
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misunderstood as an equal interval scale). When understood as a quasinormal curve, the lip and 
philtrum rankings of ‘4’ and ‘5’ are understood as the extremes of development, with ‘3’ as the 
average range. For the purposes of an FASD evaluation, rankings of ‘4’ and ‘5’ are the critical values. 
Standard deviation values can be conveniently computed using University of Washington software 
(depts.washington.edu/fasdpn/htmls/diagnostictools.htm#pfl). 
R The following three sentinel facial features should be assessed:
 y palpebral fissure length ≥2 SD below the mean
 y philtrum rated 4 or 5 on 5-point scale of the University of Washington Lip-Philtrum Guide
 y  upper lip rated 4 or 5 on 5-point scale of the University of Washington Lip-Philtrum Guide.
Rationale for revision
A minor rewording of Canadian recommendation 3.1 has removed “must be present due to their 
specificity to prenatal alcohol exposure”. The percentile threshold has been removed from the PFL 
criterion due the lack of standardised norms for this measure in the UK.
A sample FASD assessment form, which includes a section for recording of sentinel facial features is 
available for download from the SIGN website.
3.4 Neurodevelopmental assessment
3.4.1 Areas of assessment
The neurodevelopmental deficits associated with FASD are complex and multifaceted. It is well 
established that learning disabilities,77 inattention,78 social79 and executive function deficits80 can 
occur regardless of facial dysmorphology. There is no single neuropsychological measure, nor pattern 
of neuropsychological profiles that is specific to all individuals with FASD.28,81-85 It is presumed that 
differences in the dose and timing of exposure,86 as well as interacting genetic87,88 and environmental 
influences89-91 on brain development account for the variability in presentations. However, the most 
common neurodevelopmental disabilities include attention, executive function, spatial working 
memory, mathematics, communication, and adaptive behaviour.81,92,93
Canadian guidelines from 2005 and 2016 consistently recommend that significant deficits in at least 
three CNS areas of assessment are required for a diagnosis or descriptor of FASD.28,29 
High levels of variance between index scores can emerge when assessing neurobehavioural 
function.  If this discrepancy is found to be uncommon (ie a discrepancy analysis indicates this to 
occur in ≤3% of the population) and the lower of the two discrepant scores is at least one standard 
deviation below the mean, then this may be regarded as indicative of atypical development within 
that particular area of assessment.
Motor skills
Impairment is present when a composite score below the clinical cut-off or on multiple subtest scores 
is obtained on assessment of fine motor skills, gross motor skills, graphomotor skills, or visual-motor 
integration. Tone, reflexes, balance, co-ordination, strength and other abnormal findings on the 
neurological examination may be considered in combination with formal assessment of motor skills.
Neuroanatomy/neurophysiology
Impairment is present when occipitofrontal head circumference is <3rd percentile; a seizure disorder 
has been diagnosed not due to known postnatal influences; or when brain imaging shows convincing 
evidence of structural brain abnormalities known to be associated with PAE and other aetiologies 
have been excluded.94,95 Although, a magnetic resonance imaging (MRI) scan is not required or 
necessary as a standard approach to assessing an individual suspected to have FASD, it may be an 
adjunct in determining the extent of effects on the brain or to rule out other disorders.
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Cognition
Impairment is present when standardised tests of cognition or intelligence show a composite score 
below the clinical cut-off, a major subdomain score (such as verbal, nonverbal, or fluid reasoning) 
below the clinical cut off, or a large discrepancy among major subdomain scores, with a base rate 
below 3% and the lower of the two discrepant scores is at least one standard deviation below the 
mean.
Language
Impairment is present when a score below the clinical cut-off is obtained on a composite score 
assessing core language, receptive language, expressive language, or when multiple scores below 
the clinical cut off are seen on subtests assessing higher-level language skills (for example the 
integrative aspects of language such as narrative and complex comprehension abilities). Impairment 
is also present when there is a large discrepancy between receptive composite score and expressive 
composite score (as there are four index scores in language assessments), with a base rate of less than 
3% and the lower of the two discrepant scores is at least one standard deviation below the mean.
Academic achievement
Impairment is present when a score below the clinical cut-off is obtained on standardised measures 
of reading, mathematics, and/or written expression, or when there is a large discrepancy between 
cognition and one of the above, with a base rate of less than 3% and an achievement score at least 
one standard deviation below the mean. The clinical team must determine that the individual has 
had consistent exposure to academic instruction before a deficit can be recorded.
Memory
Impairment is present when a score below the clinical cut-off is obtained on a composite measure 
of overall memory, verbal memory, or visual memory, or when there is a large discrepancy between 
verbal and non-verbal memory, with a base rate of less than 3% and the lower of the two discrepant 
scores is at least one standard deviation below the mean. A deficit in working memory should be 
considered under executive function rather than memory.
Attention 
In many definitions and theories of brain function, attention overlaps with some of the executive 
functions. In order to distinguish these areas of assessment for diagnostic purposes, attention is 
here defined as sustained or selective attention and resistance to distractions. Deficits in inhibition, 
impulse control or hyperactivity should be considered under executive function rather than attention. 
Impairment in attention by direct assessment is present when multiple subtest scores below the 
clinical cut-off are obtained on continuous processing tests or other neuropsychological measures 
of attention. 
Impairment in attention by indirect assessment is present when a clinical assessment provides 
converging evidence of impairment from multiple sources, including clinical interview, questionnaire, 
file review and direct clinical observation during neurodevelopmental testing.
Executive function, including impulse control and hyperactivity
Executive function refers to a set of higher-level skills involved in organising and controlling one’s own 
thoughts and behaviours in order to meet long-term goals. Although there is some overlap between 
attention and executive function in many conceptualisations, it is here defined as impairments in 
working memory, inhibition/impulse control, hyperactivity, planning and problem solving, or shifting 
and cognitive flexibility.
Impairment in executive function by direct assessment is present when multiple subtest scores below 
the clinical cut-off are obtained on neuropsychological measures of executive function.
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Impairment in executive function by indirect assessment is present when a clinical assessment 
provides converging evidence of impairment from multiple sources, including scores at or below 
the clinical cut-off on standardised rating scales and supporting evidence from clinical interview, 
file review and direct clinical observation during neurodevelopmental testing.
Affect regulation 
Impairment of affect regulation is manifested by high levels of emotional expression resulting in 
significant clinical impairment that may take the form of anxiety or depressive disorders, or as 
oppositional-defiant or conduct disorders. Possible types of anxiety disorder are panic disorder, 
phobic disorders, separation anxiety disorder or generalised anxiety disorder. A diagnosis of 
oppositional defiant disorder or conduct disorder is manifested (in part) by a frequent loss of temper, 
arguing, becoming easily angered or annoyed, showing vindictive or other negativistic behaviours. 
Disturbances of affect regulation should only be attributed to PAE if they longstanding, and should 
not be attributed to PAE if they are formulated to be in response to unfavourable life events or 
environmental conditions (for example, multiple foster placements) or are situationally specific (for 
example, specific phobias).
Adaptive behaviour, social skills or social communication 
Impairment in social communication by direct assessment is present when a score below the clinical 
cut-off is obtained on the composite score from a measure of social language, social communication 
skills or pragmatic language skills. Impairment in adaptive behaviour or social skills by indirect 
assessment is present when according to a standardised interview or rating scale completed by a 
key informant, a score below the clinical cut-off is obtained on the global composite score or a major 
subdomain score. For children and most adolescents standardised indirect measures (ie by caregiver 
ratings) should be used. For  adults and some adolescents who have not had a consistent caregiver 
within the last two years, clinicians may need to consider other methods of interview and use of 
historical records to rate adaptive function. For social language development a direct measure with 
the client should be used, if age-appropriate, in combination with reports and historical information. 
Observations and ratings should be across environments where appropriate (ie parents report 
on experiences at home and teachers can report on behaviour at school). Scores are considered 
significant when they are below the clinical cut-off.
R  A diagnosis/descriptor of FASD is made only when there is evidence of pervasive and 
long-standing brain dysfunction, which is defined by severe impairment (a global score or 
a major subdomain score on a standardised neurodevelopmental measure that is ≥2 SDs 
below the mean, with appropriate allowance for test error) in three of more of the following 
neurodevelopmental areas of assessment:
 y motor skills
 y neuroanatomy/neurophysiology
 y cognition
 y language
 y academic achievement
 y memory
 y attention
 y executive function, including impulse control and hyperactivity
 y affect regulation, and 
 y adaptive behaviour, social skills or social communication.
Rationale for revision
This recommendation is consistent with Canadian recommendation 4.1. The term ‘domain’ has been 
replaced with area of assessment (see section 1.3.2). Adding ‘long-standing’ emphasises the existing 
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pervasive description and reinforces the concept that the impairment must be across different functional 
areas and not transient.
The definition of severe impairment has been added into this recommendation from original Canadian 
recommendation 4.2 which is now not separately listed.
A sample FASD assessment form, which includes a section for recording of neurodevelopmental areas 
of assessment is available for download from the SIGN website.
3.4.2 Direct and indirect assessment methods
Clinical training and judgment are required to interpret test results and experienced clinicians will 
evaluate scores within the context of a complete assessment picture. Canadian recommendations 
4.3, 4.4 and 4.5 regarding the use of indirect assessments were developed as a result of extensive 
discussions regarding the strengths and weaknesses of different sources of information. Direct 
testing refers to standardised testing or physical measurements. The advantages of direct testing 
include the relative objectivity and lack of observer biases. The disadvantage of direct testing 
may be the absence of ecological validity; the relative calm, structure, and lack of ambiguity in the 
testing situation may not translate to real world situations. Indirect assessment, in contrast, may 
offer more ecological validity, but also carries risk of subjective bias. There is precedent for such 
a joint approach in the routine assessment of other common neurodevelopmental disorders, such 
as intellectual disabilities, which combine direct assessment of cognition with indirect assessment 
of adaptive function.
R  Direct standardised measures should be used whenever possible. We recognise, however, that 
in some cases, indirect assessment methods such as informant ratings, clinical interview, or 
historical assessment through file review may be more appropriate.
Further details on the criteria for severe impairment in all areas of assessment and appropriate direct 
and indirect assessment methods for each is available for download from the SIGN website.
Rationale for revision
A minor revision of Canadian recommendation 4.3 has been made to simplify language and remove 
reference to ‘brain domains’.
R  If historical assessment, clinical interview, or file reviews are used for indirect assessment 
(for example assessing adaptive behaviour) deficits should be considered by the team to 
be at a severity level equal to or below the clinical cut-off, which is defined as ≥2 SD below 
the mean.
Rationale for revision
A minor revision of Canadian recommendation 4.4 has been made to clarify reference to the clinical 
cut-off.
It is incumbent that the clinician conducting the neuropsychological assessment considers the 
contribution from both the clinical interview and their clinical judgement as supporting evidence 
to confirm the significant brain impairment finding for areas of assessment that have fewer direct 
measurements. 
R  When using indirect methods of assessment, clinicians should ensure that information comes 
from multiple sources rather than a single informant.
Rationale for revision
Minor revision of Canadian recommendation 4.5 has been made to remove reference to ‘domains of 
function’.
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3.5 Special considerations in the assessment of infants, children and young people
Research has suggested that measures of infant state regulation96 and negative temperament97 are 
important indicators of FASD. Other symptoms and signs include poor eating, poor sleeping, poor 
alertness and irritability. 
Traditional tests of development in various areas of assessment are also available. The reliability of 
these tests tends to increase gradually with age, to a point where they become sufficiently reliable 
for decision-making purposes. Unfortunately, these ‘thresholds of confidence’ occur at different 
ages for different tests, and often exist as unwritten rules rather than published practice guidelines. 
The development group has provided suggestions for example neurodevelopmental tests across the 
lifespan.
R  Infants and young children with confirmed prenatal alcohol exposure, but who do not meet 
the criteria for FASD should be designated as ‘at risk for neurodevelopmental disorder and 
FASD, associated with prenatal alcohol exposure’. Those with all three facial features, but no 
microcephaly, should be referred to a clinical geneticist.
    The record of a designation of ‘at risk for neurodevelopmental disorder and FASD, associated 
with prenatal alcohol exposure’ should be available to professionals undertaking childhood 
developmental surveillance.
Rationale for revision
Canadian recommendation 7.3 has been retained in full.
R  A neurodevelopmental assessment is recommended for all children with confirmed prenatal 
alcohol exposure and/or all three facial features in whom there are clinical concerns.
Rationale for revision
Canadian recommendation 7.4 has been amended for clarity. Assessment of all children with a history 
of PAE was not thought to be practical. With the current universal developmental surveillance checks 
in place, health visitors should be aware of the potential increased risk and be proactive with early 
referral of children where there is cause for concern.
3.6 Special considerations in the assessment of adolescents and adults
Due to the current under-recognition of FASD in Scotland, presentation may occur at a later stage. Some 
young people and adults present with neurodevelopmental dysfunction where prenatal alcohol has 
not been considered as the underlying cause. Some may have already developed secondary mental 
health problems, or may have become involved in the judicial system. An awareness of the increased 
prevalence of people affected by prenatal alcohol in the mental health and judicial systems, and the 
need to review and reassess patients in these groups is required. The same guidance for assessment 
is relevant. 
    Those working in organisations related to the care of ‘looked after’ and accommodated children 
and young people, individuals being seen by mental health services, or within the judicial 
system should be aware of the increased prevalence of prenatal alcohol exposure in these 
groups, and the need for referral for assessment of impairment.
R  When it is not possible to obtain a formal adaptive behaviour measure or when there is no 
suitable informant, historical or current information, derived from a file review, may be used 
as a proxy.
Rationale for revision
Canadian recommendation 8.2 has been retained in full.
3  |  Identification and assessment of children and young people affected by prenatal alcohol exposure
24
Children and young people exposed prenatally to alcohol
3.6.1 Individualising the assessment
An individual’s social circumstances, such as homelessness, can present a significant challenge to 
the assessment process, especially their ability to attend appointments. They may also experience 
limited sleep and alcohol and substance abuse, which may affect the test results. A client-centred 
approach is needed such that the length of the assessment is tailored to the individual’s needs and 
capacity. They may have low frustration tolerance and become tired easily, and may not attend 
all the assessment sessions needed. It is especially important to access any recent assessments so 
that the usual test battery can be modified. When asking about previous testing, individuals and 
their caregivers often do not realise that some of the same tests are used in a school assessment 
or a forensic assessment as in the FASD assessment. Pregnancy, breastfeeding, and childcare 
responsibilities are stressors that can impact test results and attendance. A chronic state of crisis 
or mental health involvement may mean that there is never an ideal time to be assessed but the 
clinical team must be confident that a reliable assessment can be obtained. An FASD diagnosis/
descriptor based on unreliable data is not valid.
R  The length and structure of the assessment must accommodate the needs and capacity of 
the individual being assessed. It is important to recognise, for example, if the individual gets 
frustrated or tires easily; situational factors could invalidate the assessment.
Rationale for revision
A minor revision has been made to Canadian recommendation 8.3 in order to clarify the term 
“individual”.
3.6.2 Making the assessment meaningful
The assessment and diagnosis/descriptor of FASD can help the individual, their family, and 
service providers to understand the challenges associated with a lifelong disability that requires 
accommodations and supports to maximise success.98 It may help them access interventions and 
supports that address their biopsychosocial needs with recommendations for basic supports, 
general, physical and mental health.
R  Recommendations following the assessment must address basic and immediate needs of the 
individual being assessed, and assist them in accessing required resources.
Rationale for revision
A minor revision has been made to Canadian recommendation 8.4 in order to clarify the term “individual”.
R  The core principles of bioethics, including autonomy and consent, confidentiality, beneficence, 
and non-maleficence must be carefully applied.
Rationale for revision
A minor revision has been made to Canadian recommendation 8.5 to cover people of all ages.
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3.7 The assessment team
Because of the complexity of the outcomes related to PAE, a multidisciplinary team is essential for 
an accurate and comprehensive assessment and subsequent management recommendations. The 
multidisciplinary assessment team can be local, central or virtual; satellite clinics and telemedicine 
may be used to meet the needs of referrals from remote and rural locations. The team will vary 
according to the specific context and the age of the individuals being assessed. The team members 
should possess the necessary expertise to conduct all aspects of the assessment and have updated 
knowledge about FASD. New members of the team must receive appropriate training. Team members 
are outlined below and should always consist of professionals with appropriate qualifications, who 
have received appropriate training around obtaining sensitive information from birth families, 
especially when acquiring the prenatal alcohol exposure history.
R Team members across the lifespan are:
 y  neonatologist/paediatrician/physician with competency in assessment of FASD
 y  child development specialists with the skillset to conduct physical and functional 
assessments (eg speech and language therapist, occupational therapist, clinical psychologist, 
educational psychologist).
  Further individuals who can provide valuable input into the diagnostic process may include 
parents and carers, advocates, childcare workers, clinical geneticists, cultural interpreters, 
family therapists, general practitioners, learning support, mental health professionals, mentors, 
nurses (eg school, learning disability, etc), neuropsychologists, probation officers, psychiatrists, 
social workers, substance misuse service staff, teachers and vocational counsellors.
Rationale for revision
Canadian recommendation 6.1 has been amended to remove the term ‘core team’, and to ensure 
terminology is appropriate to NHSScotland. It has been further amended to remove the stratification 
of team members by age of individual receiving assessment.
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4 Management and follow up
4.1 Developing a management plan
Fetal alcohol spectrum disorder is a lifelong condition and individuals with FASD have varying needs 
across their lifespan. Each child is unique in their presentation, and so, no single approach is optimal 
for all cases. To allow people to live as independently as possible, services need to take a wide, varied 
and adaptable approach.
Following assessment, which should build a picture of the pattern of strengths and difficulties 
unique to the individual, management and follow up are critical to ensure that this specific profile of 
vulnerabilities is targeted for intervention. The assessment needs to be shared with the parents, carers 
and child or young person in an appropriate way, and the implications for the child’s educational needs 
and how they can function within the living environment need to be documented in a practical way for 
those working closely with the child and their family. The lifelong and changing nature of the disorder 
needs to be understood, as does the need for reassessment at stages of transition to new situations.
The assessment and diagnosis of FASD can help the individual, their family, and service providers 
to understand the challenges associated with a lifelong disability that requires accommodations and 
supports to maximise success. 
Getting It Right For Every Child (GIRFEC)62 aims to promote and support children and young people’s 
well-being by making sure they have access to the right support when they need it.  The co-ordination 
of services and collaboration between services as outlined in GIRFEC and related legislation is important 
for the provision of effective interventions and support (see section 2.1.4).
Client- and family-centred approaches that are based on strengths, and sufficiently flexible to account 
for individual barriers, should be best practices for supporting adults with FASD. Recognising common 
risks for affected individuals and acting preventively can be beneficial. Prevention education must 
be incorporated into the assessment process when working with adolescents and adults to address 
issues of sexual health, birth control, and pregnancy. Modifications to the service delivery model, 
including team composition and ways of working may be needed to support individuals throughout 
the assessment process and implementation of their management plan. The multidisciplinary team 
provides recommendations to address the basic and immediate needs of the client, and aims to assist 
the individual and their family in accessing the needed supports and services. 
4.1.1 Communicating the results of assessment
The results of the assessment should be presented to the family of the person being assessed 
(if a minor) and to the individual. A decision by the clinical team should be made regarding how 
to best present the findings to an adolescent or older child. The results should be presented in 
a written or graphical report that documents the social history, medical findings, results of the 
neurodevelopmental assessment, and diagnoses. FASD is a medical diagnosis or descriptor, and as 
such, there is unavoidable terminology that may not easily be understood by the individual and/
or their family. The clinical team should do its best to simplify the findings when presented to 
the family and be available later to answer questions that may arise from the written report. The 
recommendations in the report should include services that might be available. 
A sample diagnostic assessment summary form is available for download from the SIGN website.
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R  Education about the impact of FASD and appropriate support for the individual and those 
involved with their care is recommended. The range of potential issues that might be expected 
to arise as a result of receiving the FASD diagnosis/descriptor should also be discussed. It 
is important that this information is communicated in a culturally sensitive manner using 
appropriate language.
A range of information for individuals and caregivers, and for clinicians is available for download 
from the SIGN website. This includes information and resources about issues that individuals and their 
caregivers may experience during the FASD assessment process and after a diagnostic assessment. 
Rationale for revision
Canadian recommendation 9.1 has been amended for terminology appropriate to NHSScotland. 
‘Appropriate’ has been added as children who are affected and their families may not always require 
comprehensive support. ‘Develop’ has been changed to ‘arise’ to resolve unintended ambiguity that 
consequences of receiving a diagnosis or descriptor might represent a maturational change.
4.1.2 Follow up
Care plans99 for affected individuals and those that support them are important to improve outcomes. 
Individuals with FASD experience a wide variety of complex physical, mental and behavioural 
health-related challenges that require a multifaceted approach to diagnosis and management. The 
complexity and persistence of FASD symptoms across the lifespan necessitates a long-term plan 
for management. The types of recommended services and supports will differ based on individual 
needs, and will often depend on where patients are assessed. Clinics may consider implementing 
staged care plans across the lifespan, with the opportunity to review a patient’s current situation 
and anticipate upcoming problems at predetermined time intervals.
R  A member of the team around the child should follow up within a specified length of time to 
ensure that the recommendations have been addressed and to provide further support as 
needed.
Rationale for revision
Canadian recommendation 9.2 has been amended to align with current GIRFEC scheme and language 
appropriate to NHSScotland. The addition of ‘specified’ ensures that follow up is predetermined, 
rather than arbitrary.
R  Individuals with FASD and their caregivers should be linked to resources that can improve 
outcomes. However, just because availability of services is limited, an individual should not be 
denied an assessment and management plan. Often the identification of need is the impetus 
that leads to the developmental of resources.
Rationale for revision
In Canadian recommendation 9.3 the term ‘diagnosis’ is used. Rather than change this to ‘diagnosis/
descriptor’ the term ‘identification of need’ has been added to highlight the importance of the 
assessment process which may or may not result in a diagnosis, but will usually identify areas of 
need, prompting an individualised management plan.
4  |  Management and follow up
28
Children and young people exposed prenatally to alcohol
R  When young adults are transitioning to independent or interdependent living situations, 
they may need to undergo a reassessment to identify any changes in their adaptive function 
scores and to make any subsequent adjustments to their management plan.
Rationale for revision
A minor amendment has been made to Canadian recommendation 9.4 for clarity only.
    It is particularly important given the changing and lifelong nature of FASD that reassessment 
and revision of care plans are considered at all transition stages in the child and young person’s 
life. This should be linked to the GIRFEC process in Scotland and to the review of Individual 
Education Plans and transition to adulthood planning.
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5 Implementing the recommendations 
This section provides advice on the resource implications associated with implementing this guidance, 
and advice on audit as a tool to aid implementation. 
5.1 Implementation strategy 
Implementation of national clinical guidance is the responsibility of each NHS Board and is an 
essential part of clinical governance. Mechanisms should be in place to review care provided against 
the recommendations. The reasons for any differences should be assessed and addressed where 
appropriate. Local arrangements should then be made to implement the national guidance in individual 
hospitals, units and practices.  
It will be important in assessing improvement in identification of children and young people who fit 
the diagnosis of FASD with sentinel features or the descriptor of FASD without sentinel features to 
have systems in place that will enable regular monitoring of diagnosis rates and epidemiology. For 
those health boards using the national Support Needs System (SNS) database two codes have been 
agreed to distinguish each of the conditions: 
 y FASD with sentinel features (PK80)
 y FASD without sentinel features (L254). 
Recording may be challenging for child and adolescent mental health services (CAMHS) colleagues 
as FASD with sentinel features almost maps to FAS in the ICD-10 coding system, but FASD without 
sentinel features is not recognised as a diagnosis or descriptor which can be coded using ICD-10 or 
DSM-5. 
As the assessment is likely to be multidisciplinary, and CAMHS colleagues will be involved with others 
including paediatricians in the assessment process, it may be helpful to agree within health boards 
how best to record the identified children and young people in each category. For some this may 
involve the SNS system but where that is not in use a separate recording method may need to be 
established with the aim of facilitating monitoring the numbers of cases identified in each category 
year on year on a national basis. 
NHS Education for Scotland has published an FASD diagnostic pathway which provides a framework 
for all statutory and voluntary agencies who are involved in supporting children or young adults 
affected by or thought to be affected by FASD. Compliance with the pathway, which offers a broad 
range of guidance for the identification and diagnosis of children and young people at risk of FASD, 
represents an implementation tool for many of the recommendations contained in this guidance.
www.knowledge.scot.nhs.uk/ecomscormplayer/fasdpathway/j459160/fasd-01.html 
Following a commission from Scottish Government in 2016, the Mental Health Access Improvement 
Support Team (MHAIST) was established within Healthcare Improvement Scotland to improve access 
to Child and Adolescent Mental Health Services and Psychological Therapy services. The MHAIST is 
facilitating a neurodevelopmental collaborative working with teams across Scotland to improve the 
efficiency and effectiveness of their assessment and diagnostic pathways. This collaborative will run 
until the end of 2019 and is underpinned by quality improvement methodology (https://ihub.scot/
improvement-programmes/mental-health-portfolio/mhaist/).  
This guideline will assist those teams already involved in improving assessment and identification 
of FASD as well as supporting and monitoring of diagnostic rates. The collaborative will be a vehicle 
for implementation and future spread of best practice.
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5.2 Resource implications 
Additional resources are expected to be required as a result of these recommendations, but these will 
depend on several factors, including: 
 y  the extent to which clinicians' current practices for identifying patients with, or at risk of, FASD 
may be underdiagnosing the true extent of FASD in the Scottish population, and if FASD is currently 
underdiagnosed, whether it is disproportionately patients who are less severely affected by FASD 
who are less likely to be diagnosed in practice.
 y  the extent to which implementation of these recommendations is able to rectify any underdiagnosis 
of FASD.
 y  whether any additional costs associated with implementing the recommendations may be offset 
by a reduction in costs that currently occur in clinical practice in the longer term, in that, by 
enabling earlier diagnosis of FASD and thereby enabling earlier treatment strategies to be put in 
place to help individuals with FASD and their families and/or carers, the level of unmet need that 
has longer-term implications for affected individuals is reduced.
 y  the extent to which expected additional pressures on services for FASD and individuals at risk 
of FASD will be borne predominantly by NHS providers, and/or social care partners and/or third 
sector organisations dedicated to working with people who have or are at risk of FASD.
 y current and future trends in alcohol consumption during pregnancy.
In considering these issues, it is estimated that any resource impact is most likely to be felt in terms of 
staff costs, given the additional requirements associated with assessment and follow up of individuals 
who have (or are at risk of) an FASD diagnosis. There may also be additional costs to be borne by 
local authority social care partners and third sector organisations, which will depend on the identified 
social care needs of each individual with, or at risk of, FASD and the relevant staff members required 
to meet their needs. 
Within Scotland, a recent evaluation funded by Scottish Government compared a pilot evaluation by 
NHS Ayrshire and Arran for the assessment and diagnosis of those with FASD using a Fetal Alcohol 
Assessment and Support Team, with treatment as usual using CAMHS and Community Paediatrics 
services. The pilot team was found to be less likely to struggle to provide access to multidisciplinary 
staff required for FASD assessment, and more confident in making a formal diagnosis related to 
prenatal alcohol exposure. 
Whilst clinically successful, from a resource-use perspective it was noted that in the longer-term it 
would not be sustainable to provide FASD services in this way. It was therefore proposed FASD be 
managed within the context of wider neurodevelopmental services and mental health teams (and the 
service has since been integrated into existing CAMHS and Community Paediatrics services within NHS 
Ayrshire and Arran). This suggests it is possible to provide FASD services using existing resources, 
but the wider context in terms of the impact of altering existing service configurations needs to be 
considered.
A Children and Young People’s Mental Health Task Force (https://www.gov.scot/publications/children-
young-peoples-mental-health-task-force-preliminary-view-recommendations/) has been established 
by Scottish Government in collaboration with the Convention of Scottish Local Authorities to support 
and build on the actions in Scotland’s ten-year Mental Health Strategy (https://www.gov.scot/
publications/mental-health-strategy-2017-2027/) by setting out a whole systems approach to mental 
health services. The task force is investigating how services and community support can better meet 
the rapidly changing need seen across Scotland. It will look, in particular, at new provision for direct 
access to less intensive, education and community-based sources of help for young people, and will 
also develop a neurodevelopmental Service Framework and Specification that will improve support 
and care for children, young people and their families with neurodevelopmental concerns.
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Preliminary findings of the task force have identified workforce shortages and waiting time pressures 
on CAMHS services and recognised that in addition to building capacity and capability across services 
there needs to be more innovation and flexibility in CAMHS team structures.
In order for change to be sustainable, the task force will tackle the current issues with waiting times 
for mental health services in young people, combined with more services for those who need support 
but who don’t require a specialist service. It aims to improve coherence within the system, bringing 
in all of those who provide services to children and young people, including health boards, schools, 
social services, youth justice and the third sector.
The exact specifications of future workforce planning must be appropriate to local needs, and so any 
actual additional resource requirement cannot be quantified nationally at this stage. 
Regardless of service reconfiguration, the implementation and staffing of sustainable FASD services in 
the long term is expected to require training by professionals to their NHS and social care colleagues. 
The NHS Ayrshire and Arran pilot delivered training, on average, to 137 health, education and social 
care professionals every month. While it is not clear how many still require initial training and what 
the requirements for refresh training will be, staff training should be an anticipated ongoing resource.
5.3 Auditing current practice  
A first step in implementing a clinical practice guidance is to gain an understanding of current 
clinical practice. Audit tools designed around guideline recommendations can assist in this process. 
Audit tools should be comprehensive but not time consuming to use. Successful implementation and 
audit of recommendations requires good communication between staff and multidisciplinary team 
working. 
The guidance development group has identified the following as key points to audit to assist with the 
implementation of this guidance: 
 y the proportion of pregnant women with complete alcohol histories recorded in antenatal records
 y  the proportion of pregnant women and mothers who hold a personal child health record that 
contains a complete prenatal alcohol history
 y incidence and prevalence of diagnosis of FASD with sentinel facial features
 y incidence and prevalence of descriptor of FASD without sentinel facial features
 y  the proportion of individuals with a diagnosis/descriptor of FASD who are linked to resources to 
improve outcomes or who receive an individualised management plan
 y  the proportion of young adults with a diagnosis/descriptor of FASD and who are transitioning to 
independent or interdependent living situations who undergo reassessment to identify changes 
in adaptive function scores or make adjustments to their management plan
 y  the proportion of individuals with a diagnosis/descriptor of FASD who are offered written 
information at the time of diagnosis.
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5.4 Supporting materials
The following supporting materials are available for download from the SIGN website:
 y  qualitative synthesis on the experiences of caregivers looking after individuals with FASD
 y sample FASD assessment form
 y sample FASD assessment summary
 y  neurodevelopmental areas of assessment: criteria for severe impairment (includes examples of 
standardised tests) 
 y  Department of Health and Royal College of Paediatrics and Child Health growth charts for boys 
and girls aged 0–4 years and 2–18 years (including weight, length/height and head circumference)
 y  information on FASD assessment for individuals and caregivers
 y  information for clinicians: issues that individuals and their caregivers may experience during the 
FASD assessment process
 y information on FASD and support for individuals and caregivers after diagnosis
 y information and resources for clinicians after diagnosis
 y sample FASD management planning form.
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6 Development of the guidance
6.1 Introduction
SIGN is a collaborative network of clinicians, other healthcare professionals and patient organisations 
and is part of Healthcare Improvement Scotland. SIGN guidelines are developed by multidisciplinary 
groups of practising healthcare professionals using a standard methodology based on a systematic 
review of the evidence. Further details about SIGN and the guideline development methodology are 
contained in ‘SIGN 50: A Guideline Developer’s Handbook’, available at www.sign.ac.uk
6.2 Methods used to develop this guidance
This guidance was initially developed using standard SIGN methodology. The multidisciplinary 
development group was recruited (see section 6.3), key questions established (see Annex 1) and 
systematic review of the evidence carried out (see section 7.1) according to the methods published in 
SIGN 50. When it became clear that there was insufficient evidence available to answer key questions 
2(a–e), 3 and 4, a systematic search for guidelines on diagnosis of FAS or FASD was completed. The 
identified documents were sifted based on relevance, scope, comprehensiveness and alignment with 
the original key questions.
The guidelines selected were:
 y the Canadian guideline for diagnosis of FASD29
 y the Australian guide for the diagnosis of FASD32 
 y the German guideline for the diagnosis of FAS.100
The development group were invited to independently comment on each diagnostic system and 
provide feedback on their appropriateness, amenability to Scottish population and feasibility. The 
development group noted that the German guideline only included criteria for diagnosis of FAS and 
was less comprehensive than other systems and was not prioritised for adaptation. When considering 
the other candidates, the development group noted that the Australian guideline had been adapted 
from the Canadian guideline, though it was felt that the former had a more attractive interface and 
layout, including a comprehensive range of forms and appendices for recording of diagnostic outcomes 
and communicating these to parents and children. Evidence and Information Scientists also carried 
out an appraisal of guideline quality using the Appraisal of Guidelines for Research and Evaluation 
(AGREE) II instrument.101 The Canadian guideline scored highest on four of the six subdomains of the 
AGREE instrument (see Figure 1) and was chosen by the development group as the preferred source 
for adaptation. 
As key question 5 focuses on the experiences and views of parents and carers of individuals with FASD, 
the systematic review of quantitative studies used for other questions would not be an appropriate 
approach. Instead, a rapid synthesis of qualitative studies was completed to identify, appraise and 
summarise the evidence on the impact of providing care for people with FASD. This is available to 
download from the SIGN website.
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Figure 1: AGREE II instrument subdomain ratings of shortlisted FASD guidelines
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7 The evidence base
7.1 Systematic literature review
The evidence base for section 2.1.3 of this guidance was synthesised in accordance with SIGN 
methodology. A systematic review of the literature was carried out using an explicit search strategy 
devised by a SIGN Evidence and Information Scientist. Databases searched include Medline, Embase, 
Cinahl, PsycINFO, EBSCO Psychology and Behavioural Sciences Collection, Midwives Information and 
Resource Service (MIDIRS) and the Cochrane Library. The year range covered was 2007–2017. Internet 
searches were carried out on various websites including the US National Guidelines Clearinghouse. The 
main searches were supplemented by material identified by individual members of the development 
group. Each of the selected papers was evaluated by two Evidence and Information Scientists using 
standard SIGN methodological checklists before conclusions were considered as evidence by the 
development group.
The search strategies are available on the SIGN website, www.sign.ac.uk
7.1.1 Literature search for patient issues
At the start of the guideline development process, a SIGN Evidence and Information Scientist conducted 
a literature search for qualitative and quantitative studies that addressed patient issues of relevance to 
diagnosis of FASD. Databases searched include Medline, Embase, Cinahl and PsycINFO, and the results 
were summarised by the SIGN Public Involvement Officer and presented to the development group.
7.1.2 Literature search for cost-effectiveness evidence
The development group identified key questions with potential cost-effectiveness implications, based 
on the following criteria, where it was judged particularly important to gain an understanding of the 
additional costs and benefits of different treatment strategies:
 y treatments or assessments which may have a significant resource impact
 y opportunities for significant disinvestment or resource release
 y the potential need for significant service redesign
 y cost-effectiveness evidence could aid implementation of a recommendation.
A systematic literature search for economic evidence for these questions was carried out by a SIGN 
Evidence and Information Scientist covering the years 2007–2017. Databases searched include 
Medline, Embase and NHS Economic Evaluation Database (NHS EED). No relevant economic evidence 
was identified.
7  |  The evidence base
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7.2 Recommendations for research
The development group was not able to identify sufficient evidence to answer all of the key questions 
asked in this guidance (see Annex 1). The following areas for further research have been identified:
 y   what is the epidemiology of FASD in Scotland? 
Research should be supported by the implementation of diagnostic criteria recommended in this 
guidance and should include co-ordinated large-scale population-specific prevalence studies. As passive 
surveillance studies may underestimate the prevalence of FASD, future research should include active 
case ascertainment studies in a variety of settings including standard populations (nursery, primary 
schools, secondary school) and likely high-risk groups (ADHD clinics, looked-after and accommodated 
children, adopted children, individuals affected by homelessness or addictions and those involved 
with criminal justice).
 y  what are the optimal methods for discussing alcohol use before, during and after pregnancies?
 y  which methods of screening for alcohol use during pregnancy are most reliable in eliciting honest 
responses from those consuming alcohol?
 y  further feasibility studies on the use of meconium and  placental biomarkers using large-scale 
population-based methods.
 y  charts for assessing palpebral fissure length standardised to the UK population.
 y  research into the relationship between membership of the assessment team and speed, quality 
and consistency of diagnostic outcomes.
 y  economic studies on the cost effectiveness of identification and screening for children and young 
people exposed prenatally to alcohol, and diagnostic strategies for FASD, respectively.
7.3 Review and updating
This guideline was issued in 2019 and will be considered for review in three years. The review history, 
and any updates to the guideline in the interim period, will be noted in the review report, which is 
available in the supporting material section for this guideline on the SIGN website: www.sign.ac.uk
Comments on new evidence that would update this guideline are welcome and should be sent to the 
SIGN Executive, Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB (email: sign@sign.ac.uk).
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Annex 1
Key questions used to develop the guidance
This guidance is based on a series of structured key questions that define the target population, the intervention, 
diagnostic test, or exposure under investigation, the comparison(s) used and the outcomes used to measure 
efficacy, effectiveness, or risk. These questions form the basis of the systematic literature search. With the 
exception of key question 1, insufficient evidence was identified to answer these questions and the majority 
of the recommendations in this guidance are adapted from the Canadian guideline for diagnosis of FASD which 
did not include recommendations on targeted screening or timing of diagnosis.29 
Healthcare Improvement Scotland has published a synthesis of qualitative evidence on the experiences of 
caregivers looking after individuals with FASD to accompany this guidance which addresses key question 5. 
1.  How is alcohol consumption best measured and recorded (including methods of measurement, timing 
of measurement and information sharing between stakeholders)?
2.  What social, medical and developmental factors in children are associated with a diagnosis of FASD?
  a)   social history (eg foster care, maternal socioeconomic status, substance abuse among family 
members, parental history of criminal activity or domestic violence, maternal gravidity and 
parity, maternal age)
   b)  medical and genetic history (eg hearing/visual impairment, cardiac effects, fragile X)
   c)  physical examination (eg sentinel facial features, weight, height, microcephaly, skeletal effects)
   d)  neurodevelopmental assessment (eg neuroanatomy, cognition, language, motor skills, memory, 
attention, executive function, affect)
   e)  prenatal alcohol exposure
3. Should targeted screening or surveillance for FASD be carried out, and if so, how?
4. Does early diagnosis improve:
  a) any outcome for the child? 
  b) odds of future normal pregnancy?
5. What is the impact on parents or carers of supporting individuals with FASD?
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severely impaired)
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not met
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of assessment 
severely impaired)
CNS criteria 
not met
(<3 areas of
assessment severely
impaired)
No FASD
diagnosis
No FASD
diagnosis
No FASD
diagnosis
Assessment conclusive?*
FASD with 
sentinel facial 
features
FASD without 
sentinel facial
features
At risk‡
Microcephaly† No microcephaly
Infant / young 
child (<6 years)
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At risk‡
FASD with 
sentinel facial 
features
* Assessment conclusive = clinician conducting the neurodevelopmental assessment is satis­ed that the session was a true 
 representation of the person’s ability and that any de­cits reported were not due to extenuating circumstances. Assessments may be 
 inconclusive for children under six years of age, because some areas of assessment cannot be investigated with con­dence until the 
 person is older or because of other confounding factors, such as temporary life stress or illness. 
† Microcephaly is not the only pathway to diagnosis for infants and young children; these individuals may also receive other FASD 
 diagnoses, as speci­ed elsewhere in the algorithm, if they show three areas of substantial impairment on neurodevelopmental tests.
‡ At risk for neurodevelopmental disorder and FASD, associated with prenatal alcohol exposure. An at-risk designation includes situations 
 where a full neurodevelopmental assessment is not conclusive because of age or situational factors; therefore, FASD may not be the 
 diagnoses. Clinical judgement is recommended.
 Contribution of genetic factors should be considered in all cases and referral may be indicated in a typical cases or where PAE 
 is uncertain.
Con­rmed
absent 
UnknownCon­rmed
Annex 2
Diagnostic algorithm for FASD
Annexes
Strong
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Strong
Strong
High
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Moderate
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Annex 3
Recommendations from the Canadian guideline
This guidance is adapted from the Canadian guideline for diagnosis of FASD.29 While the guidance provides 
a rationale for revision to explain any changes which were made to each Canadian recommendation by 
the Scottish development group, the original unedited recommendations from the Canadian guideline are 
provided below for reference.
Screening, referral and support
Number Recommendation Strength* Quality†
1.1  All pregnant and post-partum women should be screened for alcohol 
use with validated measurement tools by service providers who have 
received appropriate training in their use. Women at risk for heavy 
alcohol use should receive early brief interventions (ie counselling 
and/or other services).
1.2  Referral of individuals for a possible FASD diagnosis should be made 
whenever there is evidence of or suspected prenatal alcohol exposure 
at levels associated with physical or developmental effects.
The medical assessment: family history, maternal alcohol history, physical examination,  
and differential diagnosis, 
Number Recommendation Strength Quality
2.1  The diagnostic process should include compiling a social and medical 
history and complete physical examination.
2.2  Confirmation of prenatal alcohol exposure requires documentation 
that the biological mother consumed alcohol during the index 
pregnancy based on: reliable clinical observation; self-report; reports 
by a reliable source; medical records documenting positive blood 
alcohol concentrations; alcohol treatment or other social, legal or 
medical problems related to drinking during the pregnancy. The 
presence of all 3 facial features has such high specificity to alcohol 
exposure and FASD that confirmation of alcohol exposure is not 
required when they are present. The presence of fewer than 3 facial 
features does not have the same degree of specificity and therefore 
requires other confirmation.
*  Strength of recommendation The strength of a recommendation reflects the extent to which we can be confident that 
desirable effects of an intervention outweigh undesirable effects.
†  Quality of evidence The quality of evidence reflects the extent to which confidence in an estimate of the effect is 
adequate to support a particular recommendation.
Strong High
Strong Moderate
Strong High
Strong High
Weak Moderate
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2.3  The number of type(s) of alcoholic beverages consumed (dose), the 
pattern of drinking and the frequency of drinking should all be 
documented, if possible.
2.4  Sources for confirmed prenatal alcohol history must be reliable 
and devoid of any conflict of interest. Unsubstantiated information, 
lifestyle alone, other drug use or history of alcohol exposure in 
previous pregnancies cannot, in isolation, confirm alcohol consumption 
in the index pregnancy. However, co-occurring disorders, significant 
psychosocial stressors and prenatal exposure to other substances (eg 
smoking, licit or illicit drugs) in the index and previous pregnancies 
should still be recorded, based on the known interactions of these 
substances and their effects on pregnancy outcomes for both the 
mother and her offspring.
Sentinel facial features
Number Recommendation Strength Quality
3.1  The following three sentinel facial features must be present due to 
their specificity to prenatal alcohol exposure: 
 •    palpebral fissure length below the 3rd percentile or 2 standard 
deviations below the mean
 •    philtrum rated 4 or 5 on the 5-point scale of the University of 
Washington Lip-Philtrum Guides
 •    upper lip rated 4 or 5 on the 5-point scale of the University of 
Washington Lip-Philtrum Guides.
3.2  Associated features (abnormalities such as mid-face hypoplasia, 
micrognathia, abnormal position or formation of the ears, high 
arched palate, epicanthic folds, limb abnormalities, palmar crease 
abnormalities, short-upturned nose, etc.) should be recorded, but do 
not contribute to confirming or refuting an FASD diagnosis.
3.3  Clinicians should refer to the following references, which can be 
used for real time measurement as well as photographic analysis, to 
measure palpebral fissure length:
 •    29–32 weeks102
 •    32–40 weeks102,103
 •    0–6 years102
 •    6–16+ years.102,104,105 
Strong
Strong
Strong
Strong
Moderate
Moderate
High
High
Strong High
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The neurodevelopmental assessment
Number Recommendation Strength Quality
4.1  A diagnosis of FASD is only made when there is evidence of pervasive 
brain dysfunction, which is defined by severe impairment in three 
or more of the following neurodevelopmental domains:
 •   motor skills
 •   neuroanatomy/neurophysiology
 •   cognition
 •   language
 •   academic achievement
 •   memory
 •   attention
 •   executive function, including impulse control and hyperactivity
 •   affect regulation
 •   adaptive behaviour, social skills, or social communication.
4.2  Severe impairment is defined as a global score or a major subdomain 
score on a standardized neurodevelopmental measure that is 2 or more 
standard deviations (SD) below the mean with appropriate allowance 
for test error. In some domains, large discrepancies among subdomain 
scores may be considered when a difference of this size occurs with a 
very low base rate in the population (≤3% of the population). Clinical 
assessment with converging evidence from multiple sources and DSM-
5 diagnostic criteria for certain disorders may also be considered in 
specific domains which are not easily assessed by standardized tests. 
For example, in the affect regulation domain the following diagnoses 
may be taken as an indication of severe impairment: major depressive 
disorder (with recurrent episodes), persistent depressive disorder, 
disruptive mood dysregulation disorder (DMDD), separation anxiety 
disorder, selective mutism, social anxiety disorder, panic disorder, 
agoraphobia, or generalized anxiety disorder.
4.3  Direct standardized measures should be used to assess brain domains 
whenever possible and this is recommended for the majority of 
evidence for brain dysfunction. We recognize, however, that in some 
cases it is not possible to use direct measures. In these situations, 
indirect assessment methods such as informant ratings, clinical 
interview, or historical assessment through file review may be used.
4.4  If historical assessment, clinical interview, or file reviews are used 
for indirect assessment (eg assessing adaptive behaviour) deficits 
should be considered by the team to be at a severity level equal to 
the clinical cut-off, which is defined as 2 standard deviations below 
the mean.
4.5  When using indirect methods of assessment, clinicians should ensure 
that information comes from multiple sources rather than a single 
informant rating multiple domains of function.
Strong High
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Nomenclature and terminology
Number Recommendation Strength Quality
5.1  A diagnosis of FASD may be made if an individual meets either of 
the two sets of criteria outlined below:
5.1.1 FASD with sentinel facial features 
 •    simultaneous presentation of the 3 sentinel facial features (short 
palpebral fissures, smooth philtrum and thin upper lip), AND
 •    prenatal alcohol exposure (PAE) confirmed or unknown. This 
diagnosis should not be made when PAE is confirmed absent or at 
a level definitely below that known to be associated with physical 
and/or developmental effects, AND
 •    evidence of impairment in 3 or more of the identified 
neurodevelopmental domains, or, in infants and young children, 
evidence of microcephaly.
 •    Growth impairment and other alcohol-related birth defects should 
be documented if present.
 •    Hereditary, prenatal and postnatal factors that may influence 
developmental outcome should be recorded.
 OR
5.1.2 FASD without sentinel facial features 
 •    evidence of impairment in 3 or more of the identified 
neurodevelopmental domains, AND
 •    confirmation of prenatal alcohol exposure, with the estimated 
dose at a level known to be associated with neurodevelopmental 
effects. 
 •    Growth impairment and other alcohol-related birth defects should 
be documented if present.
 •    Hereditary, prenatal and postnatal factors that may influence 
developmental outcome should be recorded.
5.2  At risk for neurodevelopmental disorder and FASD, associated with 
prenatal alcohol exposure
5.2.1  This is not a diagnosis; this is a designation that should be given to 
individuals when:
 •    there is confirmation of prenatal alcohol exposure, with the estimated 
dose at a level known to be associated with neurodevelopmental 
effects, AND
 •    CNS criteria 5.1.1 and 5.1.2 are not met
 •    there is some indication of neurodevelopmental disorder 
in combination with a plausible explanation as to why the 
neurodevelopmental assessment results failed to meet the criteria 
for significant impairment (eg patient was too young; assessment 
was incomplete, etc).
Weak Low
Strong High
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 •    Growth impairment and other alcohol-related birth defects should 
be documented if present.
 •    Hereditary, prenatal and postnatal factors that may influence 
developmental outcome should be recorded.
5.2.2  This designation may also be considered for individuals with all 3 
sentinel facial features of FASD as described in 5.1.1, who do not 
yet have documentation or evidence for the requisite 3 or more 
neurodevelopmental domain criteria or true microcephaly. (See 
recommendation 4.2). This designation should never be considered 
when PAE is confirmed absent.
5.3  FASD should now be used as a diagnostic term when prenatal alcohol 
exposure is considered to be a significant contributor to observed 
deficits that cannot be fully explained by other etiologies. Because 
the observed deficits are recognized as being multifactorial in origin, 
all other known relevant contributors (eg trauma, known genetic 
anomalies) should be documented with the FASD diagnosis as they 
have significant impact on the functional and neurological challenges 
of the affected individuals.
The diagnostic team
Number Recommendation Strength Quality
6.1 Core team members across the lifespan are:
 Infants (<18 months):
 •    Paediatrician/Physician
 •    Child development specialist who has the skill set to conduct 
physical and functional assessments (ie Speech-language 
pathologist, Physiotherapist, Occupational therapist, Clinical 
psychologist).
 Preschoolers (18 months–5 years)
 •    Paediatrician/Physician
 •    Occupational therapist
 •    Speech-language pathologist
 •    Psychologist
 School-aged children (6 years–age of majority)
 •    Paediatrician/Physician with expertise in FASD and differential 
diagnosis
 •    Occupational therapist
 •    Speech-language pathologist
 •    Psychologist
 Adults 
 •    Physician
 •    Psychologist
 •    Speech-language pathologist or Psychologist with expertise in 
language assessment.
Strong
Strong
Strong
Strong
Weak
Strong
Strong
Strong
High
High
Moderate
Low
Low
High
High
Moderate
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6.2  Additional individuals who can provide valuable input into the 
diagnostic process may include addiction counsellors, childcare 
workers, cultural interpreters, mental health professionals, parents 
or caregivers, advocates, mentors, probation officers, psychiatrists, 
teachers, vocational counsellors, nurses, clinical geneticists or 
dysmorphologists, neuropsychologists, social workers, nurse 
practitioners and family therapists.
Special considerations in the neurodevelopmental assessment of infants and young children
Number Recommendation Strength Quality
7.1  Infants and young children with all 3 sentinel facial features and 
microcephaly should be diagnosed with FASD with sentinel facial 
features; these children have a high risk of neurodevelopmental 
disorder. They should also be referred to a clinical geneticist.
7.2  Infants and young children with all 3 facial features may be 
diagnosed with FASD with sentinel facial features, if they undergo 
a comprehensive neurodevelopmental assessment and demonstrate 
deficits in 3 or more brain domains. Infants and young children with 
confirmed prenatal alcohol exposure may be diagnosed with FASD 
without sentinel facial features if they undergo a comprehensive 
neurodevelopmental assessment and demonstrate deficits in 3 or 
more brain domains.
7.3  Infants and young children with confirmed prenatal alcohol exposure, 
but who do not meet the criteria for FASD should be designated as 
at risk for neurodevelopmental disorder and FASD, associated with 
prenatal alcohol exposure. Those with all 3 facial features, but no 
microcephaly, should be referred to a clinical geneticist.
7.4  A complete neurodevelopmental assessment should be recommended 
at an age-appropriate time for all infants and young children with 
confirmed prenatal alcohol exposure and/or all 3 facial features.
Special considerations in the neurodevelopmental assessment of adolescents and adults
Number Recommendation Strength Quality
8.1  The diagnostic criteria for FASD are the same for adults as for younger 
individuals.
8.2  When it is not possible to obtain a formal adaptive behaviour 
measure or when there is no suitable informant, historical or current 
information, derived from a file review may be used as a proxy.
8.3  The length and structure of the assessment must accommodate the 
individual’s needs and capacity. It is important to recognize, for 
example, if the client gets frustrated or tires easily; situational factors 
could invalidate the assessment.
Strong
Strong
Strong
Strong
High
Low
Low
Low
Strong
Strong
Moderate
Moderate
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8.4  Recommendations following the assessment must address basic and 
immediate needs of the client, and assist them in accessing required 
resources.
8.5  The core principles of bioethics, including autonomy and consent, 
confidentiality, beneficence, and non-maleficence must be carefully 
considered, especially when dealing with adults.
Management and follow up
Number Recommendation Strength Quality
9.1  Education about the impact of FASD and support for the patient 
and those involved with their care is recommended. The potential 
psychosocial issues that might be expected to develop as a result of 
receiving the FASD diagnosis should also be discussed. It is important 
that this information is communicated in a culturally sensitive manner 
using appropriate language.
9.2  A member of the diagnostic team should follow up within a reasonable 
length of time to ensure that the recommendations have been 
addressed and to provide further support, if needed.
9.3  Individuals with FASD and their caregivers should be linked to 
resources that can improve outcomes. However, just because 
availability of services is limited, an individual should not be denied 
an assessment and management plan. Often the diagnosis is the 
impetus that leads to the developmental of resources.
9.4  When young adults are transitioning to independent living situations, 
it may require that they undergo a reassessment to identify any 
changes in their adaptive function scores and to make any subsequent 
adjustments to their management plan. 
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